After AbbVie became a formidable player in medical aesthetics overnight by swallowing Allergan, the Botox maker is beefing up the pipeline with new R&D projects.
The latest deal brings in the gene expression experts at Exicure, who is receiving $25 million upfront to discover and develop two new treatments for hair loss disorders. Utilizing its spherical nucleic acid (SNA) technology, the biotech starts with an artificial nanosphere as a scaffold, assembling single- and double-stranded nucleic acids on the surface to find molecules that could modulate antisense or RNAi pathways.
Should Allergan exercise its option on the treatments, it will pay up to $362.5 million total in milestones per program and take over clinical development and commercialization.
“We are excited to combine our knowledge of nucleic acid therapeutics with Allergan’s deep expertise in medical aesthetics to develop and commercialize innovative treatments for hair loss disorders.” Exicure CEO David Giljohann said in a statement. “This collaboration is an exciting opportunity to advance Exicure’s SNA technology in an important new therapeutic area.”
https://endpts.com/allergan-enlists...upfront-doubling-down-on-area-dear-to-abbvie/
The latest deal brings in the gene expression experts at Exicure, who is receiving $25 million upfront to discover and develop two new treatments for hair loss disorders. Utilizing its spherical nucleic acid (SNA) technology, the biotech starts with an artificial nanosphere as a scaffold, assembling single- and double-stranded nucleic acids on the surface to find molecules that could modulate antisense or RNAi pathways.
Should Allergan exercise its option on the treatments, it will pay up to $362.5 million total in milestones per program and take over clinical development and commercialization.
“We are excited to combine our knowledge of nucleic acid therapeutics with Allergan’s deep expertise in medical aesthetics to develop and commercialize innovative treatments for hair loss disorders.” Exicure CEO David Giljohann said in a statement. “This collaboration is an exciting opportunity to advance Exicure’s SNA technology in an important new therapeutic area.”
https://endpts.com/allergan-enlists...upfront-doubling-down-on-area-dear-to-abbvie/
